Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Urologix/Boston Scientific

This article was originally published in The Gray Sheet

Executive Summary

Urologix/Boston Scientific: Enter distribution agreement under which Boston Scientific obtains exclusive right to market Urologix' T3 (Transurethral Thermo-ablation Therapy) system for treatment of benign prostatic hyperplasia in all markets outside the U.S. and Japan. BSC begins exhibiting the T3 system at the British Association of Urological Surgeons meeting the week of June 24 in Edinburgh, Scotland. In the U.S., Urologix plans to submit a premarket approval application later this year for the T3 system. Nihon Kohden holds marketing rights in Japan, where an application for marketing approval already is pending...

You may also be interested in...



HBW Product Launches: New Chapter Collagen, Alkamind Acid-Kicking, GNC China, Tetra Bio Canada, More

GNC, Harbin launch supplements in China following regulatory approval; Bee Gone expands with allergy swabs; Bed, Bath & Beyond expands distribution of CBDMedic personal care products promoted by Rob Gronkowski; Tetra Bio has Canadian OK For hemorrhoid and pain relief OTCs, US and European pending; Agrozen offers Urban Daze CBD products; New Chapter portfolio expansion also includes fermented vitamins, elderberry supplements and magnesium; and Alkamind’s Acid-Kicking Coffee Alkalizer creamers help neutralize acid from coffee.

Daraprim Drug Pricing Suit Against Shkreli And Vyera May Signal Future FTC Actions

In joint complaint, the FTC and New York Attorney General allege scheme to block generic Daraprim and maintain exorbitant list price; they cite hundreds of emails the incarcerated Shkreli has exchanged with co-defendant in last six months.

Biogen Value-Based Contract Links Patient-Reported Outcomes To MS Drug Reimbursement

Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.

UsernamePublicRestriction

Register

MT006277

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel